Exendin‐443 or exenatide44 (synthetic name), which as been used in clinical practice since 2005, is an incretin mimetic45 glucagon‐like peptide‐1 (GLP‐1) analogue, which is a 39‐residue peptide with complex physiological actions46 in multiple organs, used in the treatment of type 2 diabetes mellitus.47 Exenatide acts as an agonist of the GLP‐1 receptor48 (GLP‐1R). Here, GLP1R is linked to type 2 diabetes mellitus.